Zalevsky Jonathan 4

What Happened

• Jonathan Zalevsky, Chief Research & Development Officer at Nektar Therapeutics (NKTR), was recorded as acquiring 16,500 stock options on July 24, 2026. The reported acquisition is a derivative award at $0.00 (i.e., stock options rather than a cash purchase).

Key Details

• Transaction date: 2026-07-24; reported on Form 4 filed 2026-07-24 (timely).
• Instrument: 16,500 stock options (derivative award) reported as acquired at $0.00.
• Shares owned after transaction: not specified in the provided filing.
• Footnote F1: Options were originally granted Dec 13, 2024 under the 2017 Amended & Restated Performance Incentive Plan and are subject to both performance- and time-based vesting; time-based vesting occurs monthly pro-rata over five years from grant.
• Footnote F2: The Board committee determined on July 23, 2026 that the performance-based vesting condition was satisfied, and the options vested on July 24, 2026 — but they remain subject to the remaining time-based vesting schedule.
• Filing timeliness: No late filing indicated.

Context

• This filing reports the satisfaction of a performance condition that converted previously conditional awards into vested options; it does not indicate an exercise of options or any sale of shares. The options continue to vest over time per the original time-based schedule, meaning Zalevsky cannot immediately access all shares underlying these options unless and until the remaining time-based vesting requirements are met. Awards like this are typical executive compensation and do not by themselves signal a buy or sell decision.